Pharmaceutical preparations company · E9 · Revenue $549M · -7.14% margin · -$79M FCF
The business is unprofitable at the operating level (-7.14% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 13.0% YoY. The question is whether this is cyclical or a structural shift.
Negative free cash flow of -$79M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$549M
▼ -13.0% YoY
Net Income (TTM)
$457M
▲ +1111.0% YoY
Op. Margin
-7.14%
▼ -0.2pp YoY
ROIC
-2.77%
▲ +1.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$79M
▼ -352.0% YoY
Op. Cash Flow (TTM)
-$65M
▼ -13109.5% YoY
Net Debt
-$1.24B
Net Cash Position
Cash & Equiv.
$1.37B
5Y CAGR: +19.2%
Continue Research